Endurant Capital Management LP Selecta Biosciences Inc Transaction History

Endurant Capital Management LP

$0
Q1 2024

15 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q2 2023 Aug 14, 2023	SELL	$1.04 - $1.4 $1.54 Million - $2.07 Million	-1,480,185 Reduced 68.33%	686,143 $768,000
Q1 2023 May 15, 2023	SELL	$1.15 - $1.89 $1.85 Million - $3.05 Million	-1,611,290 Reduced 42.65%	2,166,328 $3.01 Million
Q4 2022 Feb 14, 2023	SELL	$0.96 - $1.6 $154,359 - $257,265	-160,791 Reduced 4.08%	3,777,618 $4.27 Million
Q3 2022 Nov 14, 2022	SELL	$1.33 - $2.6 $895,390 - $1.75 Million	-673,226 Reduced 14.6%	3,938,409 $6.46 Million
Q2 2022 Aug 15, 2022	BUY	$0.67 - $1.4 $776,983 - $1.62 Million	1,159,677 Added 33.59%	4,611,635 $6.04 Million
Q1 2022 May 16, 2022	BUY	$1.23 - $3.31 $1.63 Million - $4.4 Million	1,328,432 Added 62.56%	3,451,958 $4.25 Million
Q4 2021 Feb 14, 2022	BUY	$2.89 - $4.43 $3.18 Million - $4.88 Million	1,102,025 Added 107.88%	2,123,526 $6.92 Million
Q3 2021 Nov 15, 2021	BUY	$3.36 - $4.62 $317,741 - $436,894	94,566 Added 10.2%	1,021,501 $4.25 Million
Q2 2021 Aug 16, 2021	BUY	$2.82 - $5.01 $42,945 - $76,297	15,229 Added 1.67%	926,935 $3.88 Million
Q1 2021 May 17, 2021	SELL	$2.92 - $5.07 $230,262 - $399,804	-78,857 Reduced 7.96%	911,706 $4.13 Million
Q4 2020 Feb 16, 2021	SELL	$1.64 - $3.42 $855,269 - $1.78 Million	-521,506 Reduced 34.49%	990,563 $3 Million
Q3 2020 Nov 16, 2020	SELL	$2.18 - $2.84 $582,624 - $759,015	-267,259 Reduced 15.02%	1,512,069 $3.75 Million
Q2 2020 Aug 14, 2020	BUY	$1.83 - $4.06 $2.79 Million - $6.19 Million	1,524,020 Added 596.93%	1,779,328 $5.05 Million
Q1 2020 May 15, 2020	BUY	$1.5 - $4.52 $344,280 - $1.04 Million	229,520 Added 890.03%	255,308 $615,000
Q4 2019 Feb 14, 2020	BUY	$1.32 - $2.47 $34,040 - $63,696	25,788 New	25,788 $61,000

Others Institutions Holding SELB

# of Institutions

Shares Held

4.67M

Call Options Held

Put Options Held

View Full List

About SELECTA BIOSCIENCES INC

Ticker SELB
Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Shares Outstandng 152,712,992
Market Cap $128M
Description
Selecta Biosciences, Inc., a clinical-stage biopharmaceutical company, engages in the research and development of nanoparticle immunomodulatory drugs for the treatment and prevention of human diseases. The company's lead therapeutic gene therapy program is SEL-302 that is in preclinical stage to improve the treatment of methylmalonic acidemia. I...

More about SELB

Track This Portfolio

Portfolio Update

Get notified when there are updates to the investment portfolio of Endurant Capital Management LP, based on Form 13F filings with the SEC.

News

Stay updated on Endurant Capital Management LP with notifications on news.

Account